明尼苏达胸肌风险评分在HeartMate 3人群中预测死亡率的验证
该研究在2016年7月至2021年7月单中心108例HeartMate 3植入者中验证明尼苏达胸肌风险评分(MPRS),显示其预测30天、90天和1年死亡率的AUC分别为0.73、0.78和0.81,1年结局优于HeartMate 3生存风险评分(AUC 0.693),MPRS每增加1分与死亡风险显著增加相关(HR 2.1,95%CI 1.5-3.0,P<0.0001)。
要点
- MPRS在HeartMate 3人群中验证,30天、90天和1年死亡率AUC分别为0.73、0.78和0.81。
- MPRS每增加1分与LVAD后死亡风险显著增加相关(HR 2.1,95%CI 1.5-3.0,P<0.0001)。
- 1年结局MPRS的AUC为0.81,高于HM3RS的0.693。
核心结论
- MPRS在此前瞻性验证中表现良好,尤其对LVAD后90天和1年死亡率;该工具可为风险分层提供额外信息以辅助知情决策。
研究设计与样本
- 单中心HeartMate 3队列,2016年7月至2021年7月,n=108,纳入MPRS计算协变量完整且植入在MPRS开发之后的受试者,计算MPRS并生成ROC曲线评估30天、90天和1年死亡率区分度,再将1年结局表现与HeartMate 3生存风险评分(HM3RS)比较。
主要发现
- 平均年龄58(15)岁,男性80%(86/108),目的地治疗26%(28/108)。
- MPRS预测LVAD后死亡率的AUC:30天0.73,90天0.78,1年0.81。
- HM3RS对1年结局的AUC为0.693。
- MPRS每增加1分与LVAD后死亡风险显著增加相关(HR 2.1,95%CI 1.5-3.0,P<0.0001)。
临床怎么用
- 作者认为该工具可为风险分层提供额外信息以辅助知情决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Minnesota Pectoralis Risk Score (MPRS) utilizes computed tomography-quantified thoracic muscle and clinical variables to predict survival after left ventricular assist device (LVAD) implantation. The model has not been prospectively tested in HeartMate 3 recipients. METHODS: A single-center HeartMate 3 cohort from July 2016 to July 2021 (n = 108) was utilized for this analysis. Cohort subjects with complete covariates for MPRS calculation (pectoralis muscle measures, Black race, creatinine, total bilirubin, body mass index, bridge to transplant status, and presence/absence of contrast) implanted after MPRS development were included. MPRS were calculated on each subject. Receiver operating characteristic curves were generated to test model discrimination at 30-day, 90-day, and 1-year mortality post-LVAD. Next, the performance of the 1-year post-LVAD outcome was compared to the HeartMate 3 survival risk score (HM3RS). RESULTS: The mean age was 58 (15 years), 80% (86/108) were male, and 26% (28/108) were destination therapy. The area under the curve (AUC) for the MPRS model to predict post-LVAD mortality was 0.73 at 30 days, 0.78 at 90 days, and 0.81 at 1 year. The AUC for the HM3RS for the 1-year outcome was 0.693. Each 1-unit point of the MPRS was associated with a significant increase in the hazard rate of death after LVAD (hazard ratio 2.1, 95% confidence interval 1.5-3.0, p < 0.0001). CONCLUSIONS: The MPRS had high performance in this prospective validation, particularly with respect to 90-day and 1-year post-LVAD mortality. Such a tool can provide additional information regarding risk stratification to aid informed decision-making.
引用
- Siems CB, Ji Z, Jedeon Z, et al. Validation of the Minnesota Pectoralis Risk Score to predict mortality in the HeartMate 3 population. J Heart Lung Transplant. 2023. PMID: 37956881. doi:10.1016/j.healun.2023.11.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。